Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session

Boston, Massachusetts, May 29, 2026 — Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the presentation of results describing Phase 2a efficacy and safety data in patients with type 2 diabetes (T2D) at the upcoming Annual American Diabetes Association (ADA) Scientific Session taking place from June 5-8, 2026, in New Orleans, LA.

The Phase 2a study (NCT02372578) is a multicenter, randomized, double-blind, placebo- and active-controlled clinical trial that enrolled participants with Type 1 diabetes (T1D) or T2D and Painful Diabetic Peripheral Neuropathy (PDPN). While the original intent of the study was to evaluate effects on neuropathic pain, the analyses presented here evaluate changes in cardiometabolic parameters, including glycemic control, with an additional assessment of a subset of patients with clinical risk factors for elevated cortisol (EC).

Conference details are as follows:

ADA 2026 – American Diabetes Association Scientific Sessions (June 5-8)

Title: Cardiometabolic Effects of Clofutriben (CLO) in Adults with Type 2 Diabetes (T2D): A 6 Week, Phase 2 Placebo-Controlled, Randomized Clinical Trial

Format: Poster Presentation

Date and Time: June 7, 12:30-1:30pm ET

Location: Ernest N. Morial Convention Center, New Orleans, LA Poster Hall (Halls D-E)

Author: Frank Czerwiec, MD, Chief Medical Officer, Sparrow Pharmaceuticals 

For more information and to connect with Sparrow Pharmaceutical representatives, visit the Sparrow booth #1745 in the Morial Convention Center.